Üriner sistem infeksiyonları, kadınlar, renal transplantlı hastalar, spinal kord hasarı bulunanlar, üriner sistem anormallikleri olan erişkinler ile bebek ve çocuklarda tekrarlayabilmektedir. Bu hasta gruplarında, profi laksi uygulaması üriner sistem infeksiyonlarının tekrarlamasını azaltmaktadır. Bu derlemede, üriner sistem infeksiyonlarının önlenmesinde uygulanan profi laksi yaklaşımları gözden geçirilmiştir.
Urinary tract infections may recur in female, renal transplant patients, people with spinal cord injury, adults with urinary tract abnormalities and infants and children. Prophylaxis can reduce recurrent urinary tract infections in these patients. In this review, prophylaxis approaches for the prevention of urinary tract infections are overviewed.
1. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol 2005; 173: 1281-7.
2. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in men. J Urol 2005; 173: 1288-94.
3. Sobel JD, Kaye D. Urinary Tract Infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 957-85.
4. Dwyer PL, O'Reilly M. Recurrent urinary tract infection in the female. Curr Opin Obstet Gynecol 2002; 14: 537-43.
5. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001; 17: 259–68.
6. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80: 331–3
7. Raz R, Colodner R, Rohana Y et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 2003; 36: 1362-8
8. Albert X, Huertas I, Pereiro II, Sanfelix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004; 3: CD001209
9. Ludwig M, Hoyme U, Weidner W. Recurrent urinary tract infection in women. Long-term antibiotic prophylaxis. Urologe A 2006; 45: 436-42
10. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993; 329: 1328-34.
11. Nicolle LE. Urinary tract infections in the elderly. J Antimicrob Chemother 1994; 33: 99-109.
12. Alexiou Z, Mouktaroudi M, Koratzanis G et al. The signifi cance of compliance for the success of antimicrobial prophylaxis in recurrent lower urinary tract infections: the Greek experience. Int J Antimicrob Agents 2007; 30: 40-3.
13. Pfau A, Sacks TG. Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women. J Urol 1994; 152: 136-8.
14. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG. Post-intercourse versus daily ciprofl oxacin prophylaxis for recurrent urinary tract infections in premenopausal women. J Urol 1997; 157: 935-9.
15. Fihn SD. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003; 349: 259–66.
16. Nicolle LE, Ronald AR. Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am 1987; 1: 793–806.
17. Nicolle LE, Harding GK, Thomson M, Kennedy J, Urias B, Ronald AR. Effi cacy of fi ve years of continuous, lowdose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis 1988; 157: 1239–42.
18. Beetz R. May we go on with antibacterial prophylaxis for urinary tract infections? Pediatr Nephrol 2006; 21: 5–13.
19. Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 19: CD001534
20. Nuutinen M, Uhari M. Recurrence and follow-up after urinary tract infection under the age of 1 year. Pediatr Nephrol 2001; 16: 69–72.
21. Garin EH, Olavarria F, Nieto VG, Valenciano B, Campos A, Young L. Clinical signifi cance of primary vesicoureteral refl ux and urinary antibiotic prophylaxis after acute pyelonephritis: A multicenter, randomized, controlled study. Pediatrics 2006; 117: 626-32.
22. Wan KS, Liu CK, Chen LH. Primary urinary tract infection in infants: prophylaxis for uncomplicated pyelonephritis. Nephrology (Carlton) 2007; 12:178-81.
23. Linshaw MA. Controversies in childhood urinary tract infections. World J Urol 1999; 17: 383-95.
24. Bollgren I. Antibacterial prophylaxis in children with urinary tract infection. Acta Paediatr Suppl 1999; 88: 48–52.
25. Sayın Kutlu S, Kutlu M. Didim’de Üriner Sistem İnfeksiyonlarından İzole Edilen E. coli Suşlarının Antibiyotik Duyarlılığı. İnfeksiyon Dergisi 2007; 21: 81-3.
26. Raz R, Chazan B, Kennes Y et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34: 1165-9.
27. Kaneko K, Ohtomo Y, Shimizu T, Yamashiro Y, Yamataka A, Miyano T. Antibiotic prophylaxis by lowdose cefaclor in children with vesicoureteral refl ux. Pediatr Nephrol 2003; 18: 468–70.
28. Thompson RH, Chen JJ, Pugach J, Naseer S, Steinhardt GF. Cessation of prophylactic antibiotics for managing persistent vesicoureteral refl ux. J Urol 2001; 166: 1465-9.
29. Coulthard MG. Do kidneys outgrow the risk of refl ux nephropathy? Pediatr Nephrol 2002; 17: 477–80.
30. Dantas SR, Kuboyama RH, Mazzali M, Moretti ML. Nosocomial infections in renal transplant patients: risk factors and treatment implications associated with urinary tract and surgical site infections. J Hosp Infect 2006; 63: 117-23.
31. Khosroshahi HT, Mogaddam AN, Shoja MM. Effi cacy of high-dose trimethoprim-sulfamethoxazol prophylaxis on early urinary tract infection after renal transplantation. Transplant Proc 2006; 38: 2062-4.
32. Valera B, Gentil MA, Cabello V, Fijo J, Cordero E, Cisneros JM. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc 2006; 38: 2414-5.
33. Rubin RH, Tolkoff-Rubin NE. Risk and epidemiology after renal transplantation. In: Bowden RA, Ljungman P, Paya CV editors, Transplant Infections. 1th ed. Phialdelphia: Lippincott Williams Wilkins; 2003. p. 99-119.
34. Naghibi M, Nazemian F. Postrenal transplantation urinary tract infections. Transplant Proc 2003; 35: 2684.
35. Munoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin Infect Dis 2001; 33: 53-7.
36. Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 2002;113 Suppl 1A:67-79
37. Salomon J, Denys P, Merle C et al. Prevention of urinary tract infection in spinal cord-injured patients: safety and effi cacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up an observational prospective study. J Antimicrob Chemother 2006; 57: 784-8.
38. Biering-Sorensen F, Hoiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V. Ciprofl oxacin as prophylaxis for urinary tract infection: prospective, randomized, crossover, placebo controlled study in patients with spinal cord lesion. J Urol 1994; 151: 105–8.
39. Reid G, Potter P, Delaney G, Hsieh J, Nicosia S, Hayes K. Ofl oxacin for the treatment of urinary tract infections and biofi lms in spinal cord injury. Int J Antimicrob Agents 2000; 13: 305–7.
40. Van der Wall E, Verkooyen RP, Mintjes-de Groot J et al. Prophylactic ciprofl oxacin for catheter-associated urinary tract infection. Lancet 1992; 339: 946–51.
41. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infection. N Engl J Med 1993; 329: 753 6.
42. Stern JA, Hsieh YC, Schaeffer AJ. Residual urine in an elderly female population: novel implications for oral estrogen replacement and impact on recurrent urinary tract infection. J Urol 2004; 171: 768-70.
43. Pinggera GM, Feuchtner G, Frauscher F et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur Urol 2005; 47: 243–9.
44. Di Martino P, Agniel R, David K et al. Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: a doubleblind randomized placebo-controlled cross-over trial. World J Urol 2006; 24: 21–7.
45. Raz R, Chazan B, Dan M. Cranberry juice and urinary tract infection. Clin Infect Dis 2004; 38: 1413-9.
46. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberrylingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001; 322: 1571-3.
47. Stothers L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products against urinary tract infection in women. Can J Urol 2002; 9: 1558-62.
48. Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004; 2: CD001321.
49. Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994; 271: 751-4.
50. Schlager TA, Anderson S, Trudell J, Hendley JO. Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization. J Pediatr 1999; 135: 698-702.
51. Reid G, Hsiehl J, Potter P et al. Cranberry juice consumption may reduce biofi lms on uroepithelial cells: pilot study in spinal cord injured patients. Spinal Cord 2001; 39: 26-30.
52. Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001; 57: 26-9.
53. Reid G, Bruce AW. Selection of lactobacillus strains for urogenital probiotic applications. J Infect Dis 2001; 183: 77-80.
54. Reid G, Bruce AW. Probiotics to prevent urinary tract infections:the rationale and evidence. World J Urol 2006; 24: 28–32.
55. Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006; 28: 30–4.
56. Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol 2007; 177: 1349-53.
57. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol 2003; 170: 867-9.
58. Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 2001; 183: 81-3.
59. Magasi P, Panovics J, Illes A, Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol 1994; 26: 137-40.
60. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of fi ve placebo-controlled double-blind studies. Int J Antimicrob Agents 2002; 19: 451-6.
61. Trautner BW, Hull RA, Darouiche RO. Escherichia coli 83972 inhibits catheter adherence by a broad spectrum of uropathogens. Urology 2003; 61: 1059-62.
62. Trautner BW, Hull RA, Darouiche RO. Prevention of catheter-associated urinary tract infection. Curr Opin Infect Dis 2005; 18: 37-41.
63. Trautner BW, Hull RA, Darouiche RO. Colicins prevent colonization of urinary catheters. J Antimicrob Chemother 2005; 56: 413-5.
64. Sunden F, Hakansson L, Ljunggren E, Wullt B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 2006; Suppl 1: 26-9.
65. Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis 2005; 41: 1531-4.